Printer Friendly

Articles from M2 Pharma (July 23, 2018)

1-20 out of 20 article(s)
Title Author Type Words
Anima Biotech declares multi-year agreement with Lilly to discover and develop translation inhibitors of certain protein targets. 363
Blade Therapeutics Commences Phase 1 Study of Calpain Inhibitor for Fibrosis. 200
Co-Diagnostics Submits CE Mark Registration for Tuberculosis Screening Test. 222
CStone Pharmaceuticals names new chief financial officer. 193
FDA, EMA Grant Inozyme Pharma Orphan Drug Designation for INZ-701. 236
Futura Medical's TPR100 to be assessed by UK regulators. 193
Homology Medicines Details In Vivo Gene Editing Capabilities of Nuclease-Free Technology Platform. 219
Immunomedics partners with AstraZeneca for combination trial. 187
Innovus Pharmaceuticals Expects Preliminary 2Q18 Sales Revenue of USD 6.6m to USD 6.8m. Financial report 169
Irvine Scientific Launches NK Cell Expansion Medium. 277
Kite collaborates with Gadeta. 149
Norgine BV opens new German office. 156
Novartis to make EUR95m payment to Galapagos and MorphoSys. 162
Owen Mumford acquires exclusive rights to sell and distribute rapid diagnostic HIV test in Europe. 152
Phase 3 Renal Outcomes Trial of Invokana Stopped Early Based on Positive Efficacy. 320
Presage Biosciences Raises USD 6m in Series D Financing. 226
Sinovant Sciences Partners with Renexxion to Develop Naronapride in China. 273
Spherix Quarterly Study Shows Growth in Use of Taltz in Psoriatic Arthritis While Use of Xeljanz Remains Flat. 242
STA Pharmaceutical collaborates with Antengene. 158
Titan Spine names Peter Wehrly to board of directors. 222

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters